Sonora Investment Management Group LLC Has $10.31 Million Position in Pfizer Inc. (NYSE:PFE)

Sonora Investment Management Group LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 406,837 shares of the biopharmaceutical company's stock after purchasing an additional 48,089 shares during the period. Sonora Investment Management Group LLC's holdings in Pfizer were worth $10,309,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Tallon Kerry Patrick acquired a new stake in Pfizer during the 4th quarter worth $509,000. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the period. Strategic Financial Concepts LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $2,281,000. Finally, Vest Financial LLC increased its stake in Pfizer by 15.1% during the 4th quarter. Vest Financial LLC now owns 27,234 shares of the biopharmaceutical company's stock worth $723,000 after purchasing an additional 3,573 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 1.3%

PFE traded down $0.33 on Friday, hitting $24.51. 46,354,360 shares of the company were exchanged, compared to its average volume of 41,162,088. The stock's fifty day moving average is $23.01 and its 200-day moving average is $24.97. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $139.35 billion, a PE ratio of 17.38, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.82 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.02%. Pfizer's payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PFE. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.